Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - April 24, 2025
SPT-320, a First-in-Class Prodrug of Agomelatine that AvoidsFirst-Pass Hepatic Metabolism via Lymphatic System Absorption
SPTX Positive Sentiment
SPT-320, a First-in-Class Prodrug of Agomelatine that AvoidsFirst-Pass Hepatic Metabolism via Lymphatic System Absorption
Key Takeaway: SPT-320 is introduced as a first-in-class prodrug of Agomelatine, designed to bypass first-pass hepatic metabolism through absorption in the lymphatic system. This novel mechanism could potentially improve the drug's therapeutic effects. The announcement highlights the innovative nature of SPT-320 in the pharmaceutical landscape.
Market Sentiment Analysis
POSITIVE FACTORS
- SPT-320 is a first-in-class prodrug of Agomelatine.
- It utilizes lymphatic system absorption to avoid first-pass metabolism.
- This innovative approach may enhance drug efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is SPT-320?
SPT-320 is a first-in-class prodrug of Agomelatine.
How does SPT-320 work?
It avoids first-pass hepatic metabolism through lymphatic system absorption.
What are the benefits of SPT-320?
Its innovative absorption method may enhance drug efficacy.